NYU, MRCT in antibody deal for osteolysis

U.K.-based not-for-profit MRC Technology partnered with New York University School of Medicine to develop antibodies against the university's targets to treat inflammatory osteolysis, a disease involving breakdown and resorption of bone.

Nadim Shohdy, director of drug discovery partnerships at NYU, would not disclose the targets but said they consist of an axon guidance molecule and its receptors. Shohdy said both partners will conduct research, but MRCT will develop the antibodies. Each partner will fund its own research; the two will share royalties from any approved drugs emerging from the collaboration. ...